Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HRS-5817 in Obese Participants
NCT07238647Phase 1Active, not recruiting
- Sponsor
- Atridia Pty Ltd
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Nucleic Acid Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of HRS-5817 in obesity (4 arms), sponsored by Atridia Pty Ltd. Primary endpoint: Treatment Emergent Adverse Events at Day 253. Started Jan 2026; status: active, not recruiting.
02
Drugs
HRS-5817
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07238647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07238647.